Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.

Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand, the company’s full-year ...

Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life science tools group will likely continue to work ...

RESEARCH TRIANGLE PARK, N.C., January 13, 2025--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence ...

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, life sciences services company IQVIA Holdings Inc. (IQV) initiated its adjusted earnings and revenue guidance for ...

Companies including Illumina (ILMN) and IQVIA (IQV) are currently using Nvidia technology. The tech giant said that its technology, such as AI processes, can accelerate clinical trials by reducing ...

How Virtual Clinical Trials Are Speeding The Path To Another Vaccine For decades, IQVIA has been helping pharmaceutical giants perform clinical trials to test new treatments. The company combines ...